Comparative Effect of Citalopram and Escitalopram in the Patients with Schizophrenia

Comparative Effect of Citalopram and Escitalopram in the Management of Depressive Symptoms among Patients with Schizophrenia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190525043700N1

Enrollment

Registered

2019-10-11

Start date

2019-02-20

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Depression. Condition 2: Schizophrenia. Major depressive disorder, single episode, mild Schizophrenia

Interventions

Intervention 1: Intervention group: Treatment with citalopram (Ramofarmine Co) started at 10 mg and gradually increased to 40 mg daily. Intervention 2: Intervention group2: Treatment with Sitalopram (

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of schizophrenia based on DSM-IV TR structured clinical interview by a psychiatrist (faculty member and psychiatry resident) Diagnosis of depression based on DSM-IV TR structured clinical interview by a psychiatrist (faculty member and psychiatry resident)

Exclusion criteria

Exclusion criteria: Drug abuse Epilepsy Ischemia Heart Disease Heart Failure Mental retardation Parkinson

Design outcomes

Primary

Measure	Time frame
Patient´s depressive condition. Timepoint: Before intervention (first visit) ,the end of the fourth week (second visit),the end of the eighth week (third visit). Method of measurement: (Calgary Depression Scale for Schizophrenia (CDSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRomina Hamzehpour

Babol University of Medical Sciences

r.hamzehpour@mubabol.ac.ir+98 11 3233 8301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026